Arcalion 200 Mechanism of Action

Pharmacotherepeutic Group: Antiasthenic drug.
Pharmacology: In Animals: Pharmacological studies carried out in animals, either with acute or chronic administration, have evidenced the following actions: Sulbutiamine increases physical resistance to fatigue, neuromuscular efficiency and learning and memory; and improves the metabolic functions of the cerebral cortex.
In Man: The activity of sulbutiamine has been studied in functional asthenia in the course of controlled clinical studies (against placebo or reference products) using psychometric scales (Middlesex Hospital Questionnaire, Crocq Scale for the evaluation of nonpsychotic depressive conditions, Lipman auto-evaluation scale), with statistical analysis of the results. These studies showed the activity of sulbutiamine in the symptomatic treatment of functional asthenia.
Pharmacokinetics: Sulbutiamine is rapidly absorbed and the blood concentration is maximum in 1-2 hrs after oral administration. The molecule is rapidly distributed in the whole organism and is eliminated with a biological half-life of 5 hrs.
The urinary excretion is maximal 2-3 hrs after administration.